AstraZeneca’s Fasenra has been awarded Orphan Drug Designation in the US for the treatment of hypereosinophilic syndrome (HES).Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.